Journal of Clinical Oncology, Vol 13, 1355-1360, Copyright © 1995 by American Society of Clinical Oncology
Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma
G Nadali, F Vinante, H Stein, G Todeschini, C Tecchio, L Morosato, M Chilosi, F Menestrina, MC Kinney and JP Greer
Department of Hematology, Verona University School of Medicine, Italy.
PURPOSE: To determine serum levels of the soluble form of CD30 molecule
(sCD30) in patients with Ki-1/CD30+ anaplastic large-cell lymphoma (ALCL),
and to evaluate its correlation with clinical features at presentation and
its possible role as a tumor marker to monitor response to treatment and
subsequent follow-up. PATIENTS AND METHODS: sCD30 serum levels were
measured with an improved commercial sandwich enzyme-linked immunosorbent
assay (ELISA) test kit in 24 patients with CD30+ ALCL at diagnosis and in
13 after treatment. RESULTS: Increased values (> 20 U/mL) at diagnosis
were observed in 23 of 24 cases (median, 842.5 U/mL; range, 16 to 37,250)
as compared with controls (P < .0001). These values were greater than
those of 60 stage-matched cases of Hodgkin's disease (HD) (P < .0001).
The highest median value was observed in patients with T-cell-type ALCL
(1,690 U/mL), with a significant overall difference as compared with B- and
null-cell types (P = .004). Phenotype maintained its significance when
results were corrected for other parameters, such as age, sex, and stage (P
= .03). sCD30 values returned to the normal range in complete remission
(CR), but remained increased in one patient who only partially responded to
treatment. Subsequent increases of sCD30 levels were recorded in four of
four patients after relapse. CONCLUSION: sCD30 appears to be a new biologic
serum tumor marker of possible use in the clinical setting of CD30+ ALCL.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J. E. Janik, J. C. Morris, S. Pittaluga, K. McDonald, M. Raffeld, E. S. Jaffe, N. Grant, M. Gutierrez, T. A. Waldmann, and W. H. Wilson
Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma
Blood,
November 15, 2004;
104(10):
3355 - 3357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Gerli, C. Lunardi, and C. Pitzalis
Unmasking the anti-inflammatory cytokine response in rheumatoid synovitis
Rheumatology,
December 1, 2002;
41(12):
1341 - 1345.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Stein, H.-D. Foss, H. Durkop, T. Marafioti, G. Delsol, K. Pulford, S. Pileri, and B. Falini
CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features
Blood,
December 1, 2000;
96(12):
3681 - 3695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Kadin
Regulation of CD30 Antigen Expression and Its Potential Significance for Human Disease
Am. J. Pathol.,
May 1, 2000;
156(5):
1479 - 1484.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Croager, A. M. Gout, and L. J. Abraham
Involvement of Sp1 and Microsatellite Repressor Sequences in the Transcriptional Control of the Human CD30 Gene
Am. J. Pathol.,
May 1, 2000;
156(5):
1723 - 1731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Duckett and C. B. Thompson
CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival
Genes & Dev.,
November 1, 1997;
11(21):
2810 - 2821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Tilly, P. Gaulard, E. Lepage, C. Dumontet, J. Diebold, I. Plantier, F. Berger, M. Symann, T. Petrella, P. Lederlin, et al.
Primary Anaplastic Large-Cell Lymphoma in Adults: Clinical Presentation, Immunophenotype, and Outcome
Blood,
November 1, 1997;
90(9):
3727 - 3734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
